購物車 
-
Valbenazine tosylate
- names：
(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate di(4-methylbenzenesulfonate)
- CAS號(hào)：
1639208-54-0
MDL Number： - MF(分子式)： C38H54N2O10S2 MW(分子量)： 762.974
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (￥) | 現(xiàn)價(jià)(￥) | 特價(jià)(￥) | 庫存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|
- 大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購物車 立即購買
| 中文別名 | (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate di(4-methylbenzenesulfonate) |
| 英文別名 | Valbenazine tosylate; NBI-98854; NBI 98854; NBI98854; MT-5199; MT 5199; MT5199; NBI-98854 ditosylate; Valbenazine ditosylate; Valbenazine tosylate; Ingrezza; |
| CAS號(hào) | 1639208-54-0 |
| Inchi | InChI=1S/C24H38N2O4.2C7H8O3S/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4;2*1-6-2-4-7(5-3-6)11(8,9)10/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3;2*2-5H,1H3,(H,8,9,10)/t17-,19-,20-,23+;;/m1../s1 |
| InchiKey | BXGKAGLZHGYAMW-TZYFFPFWSA-N |
| 分子式 Formula | C38H54N2O10S2 |
| 分子量 Molecular Weight | 762.974 |
| 溶解度Solubility | |
| 性狀 | Solid powder |
| 儲(chǔ)藏條件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 產(chǎn)品說明 | Valbenazine tosylate(CAS:1639208-54-0 ):僅限應(yīng)用于工業(yè)或者科學(xué)研究過程中非醫(yī)療目的，不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。 |
| Introduction | Valbenazine, also known as NBI-98854 and MT-5199, is a potent and selective VMAT2 inhibitor. NBI-98854 is effective in regulating the levels of dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines. NBI-98854 is promising agent for the treatment of tardive dyskinesia.NBI-98854 significantly improved tardive dyskinesia and was well tolerated in patients. These results support the phase 3 clinical trials of NBI-98854 now underway. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Patel RS, Mansuri Z, Motiwala F, Saeed H, Jannareddy N, Patel H, Zafar MK. A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. Ther Adv Psychopharmacol. 2019 May 20;9:2045125319847882. doi: 10.1177/2045125319847882. eCollection 2019. Review. PubMed PMID: 31205680; PubMed Central PMCID: PMC6535739. |
| [2]Stahl SM. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS Spectr. 2018 Aug;23(4):239-247. doi: 10.1017/S1092852918001219. Review. PubMed PMID: 30160230. |
| [3] Touma KTB, Scarff JR. Valbenazine and Deutetrabenazine for Tardive Dyskinesia. Innov Clin Neurosci. 2018 Jun 1;15(5-6):13-16. Review. PubMed PMID: 30013814; PubMed Central PMCID: PMC6040721. |
| [4] Harriott ND, Williams JP, Smith EB, Bozigian HP, Grigoriadis DE. VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111. doi: 10.1016/bs.pmch.2017.12.002. Epub 2018 Mar 7. Review. PubMed PMID: 29680151. |
| [5] Sarva H, Henchcliffe C. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. Expert Rev Clin Pharmacol. 2018 Mar;11(3):209-217. doi: 10.1080/17512433.2018.1429264. Epub 2018 Jan 23. Review. PubMed PMID: 29338466. |
6: Müller T. Valbenazine for the treatment of tardive dyskinesia. Expert Rev Neurother. 2017 Dec;17(12):1135-1144. doi: 10.1080/14737175.2017.1386556. Epub 2017 Oct 12. Review. PubMed PMID: 28971695.7: Freudenreich O, Remington G. Valbenazine for Tardive Dyskinesia. Clin Schizophr Relat Psychoses. Summer 2017;11(2):113-119. doi: 10.3371/CSRP.OFGR.071717. Review. PubMed PMID: 28742396.8: Kim ES. Valbenazine: First Global Approval. Drugs. 2017 Jul;77(10):1123-1129. doi: 10.1007/s40265-017-0770-9. Review. PubMed PMID: 28578484.9: Citrome L. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017 Jul;71(7). doi: 10.1111/ijcp.12964. Epub 2017 May 12. Review. PubMed PMID: 28497864.10: Barquero N. Valbenazine for the treatment of tardive dyskinesia. Drugs Today (Barc). 2016 Dec;52(12):665-672. doi: 10.1358/dot.2016.52.12.2570977. Review. PubMed PMID: 28276538.
對(duì)不起，暫無產(chǎn)品評(píng)價(jià)！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
胞插件.png)
細(xì)胞培養(yǎng)耗材技術(shù)領(lǐng)先性
細(xì)胞培養(yǎng)板行業(yè)面臨的核心痛點(diǎn)是：常規(guī)TC處理后表面親水角隨時(shí)間衰減，影響長期培養(yǎng)穩(wěn)定性，BIOFOUNT高分...
2026/4/28 15:12:51
胞培養(yǎng)板.jpg)
細(xì)胞培養(yǎng)耗材關(guān)鍵性能
細(xì)胞培養(yǎng)板的水接觸角作為表面潤濕性的核心指標(biāo)，直接影響細(xì)胞貼壁、增殖、分化及功能表達(dá)，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產(chǎn)替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對(duì)銅、鐵和其他重金屬?的偏好顯著高于對(duì)鈉、鉀等一價(jià)陽離子的偏好。它對(duì)二價(jià)...
2025/11/4 14:22:46
9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個(gè)重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是：微流控...
2023/7/27 12:44:28
